Short Interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Drops By 85.4%

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 1,269 shares, a decline of 85.4% from the August 15th total of 8,695 shares. Based on an average daily trading volume, of 24,351 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Oaktree Acquisition Corp. III Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Oaktree Acquisition Corp. III Life Sciences currently has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Stock Up 0.1%

OACC stock traded up $0.01 during trading on Friday, reaching $10.78. 850 shares of the company were exchanged, compared to its average volume of 36,212. The stock’s 50 day moving average price is $10.75 and its 200 day moving average price is $10.70. Oaktree Acquisition Corp. III Life Sciences has a 52-week low of $10.44 and a 52-week high of $10.88.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last issued its earnings results on Wednesday, August 12th. The company reported $0.07 earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences

Several hedge funds have recently bought and sold shares of the company. Rangeley Capital LLC raised its holdings in Oaktree Acquisition Corp. III Life Sciences by 52.8% during the first quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock worth $647,000 after purchasing an additional 21,156 shares during the last quarter. DLD Asset Management LP increased its position in shares of Oaktree Acquisition Corp. III Life Sciences by 0.9% in the first quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock valued at $1,447,000 after buying an additional 1,200 shares in the last quarter. Lineage Point Capital LP purchased a new position in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at $2,461,000. Empyrean Capital Partners LP raised its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 20.0% during the 4th quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock worth $9,522,000 after buying an additional 150,000 shares during the last quarter. Finally, Radcliffe Capital Management L.P. raised its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 67.1% during the 4th quarter. Radcliffe Capital Management L.P. now owns 377,065 shares of the company’s stock worth $3,989,000 after buying an additional 151,403 shares during the last quarter.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.